Literature DB >> 34097295

How should we define cure after parathyroidectomy for normocalcemic primary hyperparathyroidism? A retrospective cohort study.

Oscar Cano-Valderrama1,2,3, Santiago Ochagavía4,5, Concepción Sanabria6, Cristina Familiar6, Jesús Díaz4, Sara Picazo4, Patricia Sáez-Carlin4,7, Antonio J Torres4,5,7.   

Abstract

Cure after surgery for normocalcemic primary hyperparathyroidism (NHPT) is defined as parathyroid hormone (PTH) normalization. However, an increase of PTH is frequently observed in cured patients with hypercalcemic primary hyperparathyroidism (HHPT). Therefore, this criterion must be redefined. A single-center retrospective study was performed including all patients who underwent surgery for Primary Hyperparathyroidism from 2013 to 2019. Cure rates of different types of hyperparathyroidism were analyzed. PTH reduction was studied as a possible criterion to define cure in patients with NHPT. One-hundred and eighty-six patients were included: 173 with HHPT and 13 with NHPT. After a mean follow-up of 33.4 months, 174 (93.6%) patients were considered cured. Cure was more frequent in the group of patients with HHPT (97.1% vs. 46.2%, p < 0.001). In the multivariate analysis, surgical failure was associated with NHPT and multiglandular disease. Forty-nine (30.1%) cured patients with HHPT had an increased PTH during the follow-up. When decline of PTH levels was studied in patients with HHPT to define cure, the area under curve was 0.92. A cut-off value of 40% in PTH reduction achieved a sensitivity and specificity of 83.4% and 80.0%. If cure was defined as a 40% reduction of PTH, cure rate in the group of patients with NHPT would increase to 69.2%. Patients with NHPT had a lower cure rate than patients with HHPT. A significant number of cured patients with HHPT had an increased PTH during follow-up. A 40% reduction in PTH levels is proposed as an alternative definition for cure in patients with NHPT.

Entities:  

Keywords:  Cure; Hypercalcemic primary hyperparathyroidism; Normocalcemic primary hyperparathyroidism; Parathyroid gland; Parathyroidectomy; Primary hyperparathyroidism; Remission; Surgery; morbidity

Year:  2021        PMID: 34097295     DOI: 10.1007/s13304-021-01108-1

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  23 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

2.  Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism.

Authors:  S Bannani; N Christou; C Guérin; A Hamy; F Sebag; M Mathonnet; P Guillot; C Caillard; C Blanchard; E Mirallié
Journal:  Br J Surg       Date:  2018-02       Impact factor: 6.939

3.  Normocalcemic primary hyperparathyroidism.

Authors:  M R Wills; C Y Pak; W G Hammond; F C Bartter
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

Review 4.  Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.

Authors:  Joaquín Gómez-Ramírez; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2017-08-19       Impact factor: 3.445

5.  Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone.

Authors:  Gérard Maruani; Alexandre Hertig; Michel Paillard; Pascal Houillier
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

6.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

Authors:  John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

7.  Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?

Authors:  Joaquin Gómez-Ramírez; Adela Gómez-Valdazo; Patricia Luengo; Belen Porrero; Irene Osorio; Sonia Rivas
Journal:  Am J Surg       Date:  2019-10-22       Impact factor: 2.565

8.  Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

Authors:  Elena Tsourdi; M Carola Zillikens; Christian Meier; Jean-Jacques Body; Elena Gonzalez Rodriguez; Athanasios D Anastasilakis; Bo Abrahamsen; Eugene McCloskey; Lorenz C Hofbauer; Nuria Guañabens; Barbara Obermayer-Pietsch; Stuart H Ralston; Richard Eastell; Jessica Pepe; Andrea Palermo; Bente Langdahl
Journal:  J Clin Endocrinol Metab       Date:  2020-10-26       Impact factor: 5.958

9.  Response to Letter to the Editor: "Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History".

Authors:  Marian Schini; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

10.  Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Selvihan Beysel; Mustafa Caliskan; Muhammed Kizilgul; Mahmut Apaydin; Seyfullah Kan; Mustafa Ozbek; Erman Cakal
Journal:  BMC Cardiovasc Disord       Date:  2019-05-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.